Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference
May 03 2023 - 7:26AM
Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the
“Company”), a biotechnology company focused on the discovery,
research, and development of innovative treatments for Central
Nervous System (CNS) disorders, today announced its CEO, Tiago Reis
Marques, and its VP of Business Development, Mathew Lazarus will
participate in the EF Hutton Global Conference, held in New York
City, May 10-11, taking one-on-one meetings during Wednesday May
10, 2023.
About the EF Hutton Global
Conference
The conference will feature senior executives
from approximately 150 private and public companies from a wide
variety of sectors, including Consumer & Retail, Energy &
Infrastructure, Financial Services, Healthcare & Life Sciences,
Industrials, Real Estate, Gaming & Lodging, Sustainability, and
Technology, Media & Telecommunications. EF Hutton will be
showcasing dynamic public and private companies across multiple
sectors in an intimate conference setting, utilizing an impactful
and productive one-on-one format. This comprehensive, two-day event
provides company executives and investors the opportunity to
interact with each other in a friendly, high-energy
environment.
About Pasithea
Therapeutics Corp.
Pasithea Therapeutics
is a biotechnology company primarily focused on the discovery,
research and development of innovative treatments for central
nervous system (CNS) disorders. With an experienced team of experts
in the fields of neuroscience and psychopharmacology, Pasithea is
developing new molecular entities for the treatment of neurological
disorders, including Amyotrophic Lateral Sclerosis (ALS) and
Multiple Sclerosis (MS), Neurofibromatosis type 1 (NF1) and Noonan
syndrome.
Forward
Looking Statements
This press release
contains statements that constitute “forward-looking statements.”
Forward-looking statements are subject to numerous conditions, many
of which are beyond the control of the Company. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to the Company
on the date of this release. These forward-looking statements are
based upon current estimates and assumptions and are subject to
various risks and uncertainties, including, without limitation,
those set forth in the Company’s filings with the U.S. Securities
and Exchange Commission (SEC). Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company
ContactDr. Tiago Reis MarquesChief Executive OfficerEmail:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
RelationsDan SchneidermanChief Financial OfficerEmail:
dschneiderman@pasithea.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jul 2023 to Jul 2024